|
1
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Blechacz B and Gores GJ:
Cholangiocarcinoma: Advances in pathogenesis, diagnosis and
treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Valle JW: Advances in the treatment of
metastatic or unresectable biliary tract cancer. Ann Oncol 21
Suppl. 7:vii345–vii348. 2010.
|
|
4
|
Valle JW, Furuse J, Jitlal M, Beare S,
Mizuno N, Wasan H, Bridgewater J and Okusaka T: Cisplatin and
gemcitabine for advanced biliary tract cancer: A meta-analysis of
two randomised trials. Ann Oncol. 25:391–398. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davis RJ, Welcker M and Clurman BE: Tumor
suppression by the Fbw7 ubiquitin ligase: Mechanisms and
opportunities. Cancer Cell. 26:455–464. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan Y, Sangfelt O and Spruck C: The
Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett.
271:1–12. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Onoyama I and Nakayama KI: Fbxw7 in cell
cycle exit and stem cell maintenance: Insight from gene-targeted
mice. Cell Cycle. 7:3307–3313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takeishi S, Matsumoto A, Onoyama I, Naka
K, Hirao A and Nakayama KI: Ablation of Fbxw7 eliminates
leukemia-initiating cells by preventing quiescence. Cancer Cell.
23:347–361. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wertz IE, Kusam S, Lam C, Okamoto T,
Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al:
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1
and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ibusuki M, Yamamoto Y, Shinriki S, Ando Y
and Iwase H: Reduced expression of ubiquitin ligase FBXW7 mRNA is
associated with poor prognosis in breast cancer patients. Cancer
Sci. 102:439–445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Imura S, Tovuu LO, Utsunomiya T, Morine Y,
Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Takasu C, et
al: The role of Fbxw7 expression in hepatocellular carcinoma and
adjacent non-tumor liver tissue. J Gastroenterol Hepatol.
29:1822–1829. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yokobori T, Mimori K, Iwatsuki M, Ishii H,
Tanaka F, Sato T, Toh H, Sudo T, Iwaya T, Tanaka Y, et al: Copy
number loss of FBXW7 is related to gene expression and poor
prognosis in esophageal squamous cell carcinoma. Int J Oncol.
41:253–259. 2012.PubMed/NCBI
|
|
13
|
Kurashige J, Watanabe M, Iwatsuki M,
Kinoshita K, Saito S, Hiyoshi Y, Kamohara H, Baba Y, Mimori K and
Baba H: Overexpression of microRNA-223 regulates the ubiquitin
ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer.
106:182–188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang H, Lu X, Liu Z, Chen L, Xu Y, Wang Y,
Wei G and Chen Y: FBXW7 suppresses epithelial-mesenchymal
transition, stemness and metastatic potential of cholangiocarcinoma
cells. Oncotarget. 6:6310–6325. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Enkhbold C, Utsunomiya T, Morine Y, Imura
S, Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Ishikawa
D and Shimada M: Loss of FBXW7 expression is associated with poor
prognosis in intrahepatic cholangiocarcinoma. Hepatol Res.
44:E346–E352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
TNM classification of malignant tumorsInt
Union Again Cancer (UICC). 7th. New York: Wiley-Liss; 2009
|
|
17
|
Huang W, Guo L, Liu H, Zheng B, Ying J and
Lv N: C-MYC overexpression predicts aggressive transformation and a
poor outcome in mucosa-associated lymphoid tissue lymphomas. Int J
Clin Exp Pathol. 7:5634–5644. 2014.PubMed/NCBI
|
|
18
|
Welcker M, Orian A, Jin J, Grim JE, Harper
JW, Eisenman RN and Clurman BE: The Fbw7 tumor suppressor regulates
glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein
degradation. Proc Natl Acad Sci USA. 101:9085–9090. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yada M, Hatakeyama S, Kamura T, Nishiyama
M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and
Nakayama KI: Phosphorylation-dependent degradation of c-Myc is
mediated by the F-box protein Fbw7. EMBO J. 23:2116–2125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Singh AM and Dalton S: The cell cycle and
Myc intersect with mechanisms that regulate pluripotency and
reprogramming. Cell Stem Cell. 5:141–149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Spencer CA and Groudine M: Control of
c-myc regulation in normal and neoplastic cells. Adv Cancer Res.
56:1–48. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Grandori C, Cowley SM, James LP and
Eisenman RN: The Myc/Max/Mad network and the transcriptional
control of cell behavior. Annu Rev Cell Dev Biol. 16:653–699. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matsuoka S, Oike Y, Onoyama I, Iwama A,
Arai F, Takubo K, Mashimo Y, Oguro H, Nitta E, Ito K, et al: Fbxw7
acts as a critical fail-safe against premature loss of
hematopoietic stem cells and development of T-ALL. Genes Dev.
22:986–991. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Iwatsuki M, Mimori K, Ishii H, Yokobori T,
Takatsuno Y, Sato T, Toh H, Onoyama I, Nakayama KI, Baba H and Mori
M: Loss of FBXW7, a cell cycle regulating gene, in colorectal
cancer: Clinical significance. Int J Cancer. 126:1828–1837.
2010.PubMed/NCBI
|
|
25
|
Yokobori T, Mimori K, Iwatsuki M, Ishii H,
Onoyama I, Fukagawa T, Kuwano H, Nakayama KI and Mori M:
P53-Altered FBXW7 expression determines poor prognosis in gastric
cancer cases. Cancer Res. 69:3788–3794. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mao JH, Kim IJ, Wu D, Climent J, Kang HC,
DelRosario R and Balmain A: FBXW7 targets mTOR for degradation and
cooperates with PTEN in tumor suppression. Science. 321:1499–1502.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yokobori T, Yokoyama Y, Mogi A, Endoh H,
Altan B, Kosaka T, Yamaki E, Yajima T, Tomizawa K, Azuma Y, et al:
FBXW7 mediates chemotherapeutic sensitivity and prognosis in
NSCLCs. Mol Cancer Res. 12:32–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang L, Ye X, Liu Y, Wei W and Wang Z:
Aberrant regulation of FBW7 in cancer. Oncotarget. 5:2000–2015.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Akhoondi S, Sun D, von der Lehr N,
Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D,
Marth C, et al: FBXW7/hCDC4 is a general tumor suppressor in human
cancer. Cancer Res. 67:9006–9012. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kimura T, Gotoh M, Nakamura Y and Arakawa
H: HCDC4b, a regulator of cyclin E, as a direct transcriptional
target of p53. Cancer Sci. 94:431–436. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mao JH, Perez-Losada J, Wu D, Delrosario
R, Tsunematsu R, Nakayama KI, Brown K, Bryson S and Balmain A:
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor
gene. Nature. 432:775–779. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu Y, Sengupta T, Kukreja L and Minella
AC: MicroRNA-223 regulates cyclin E activity by modulating
expression of F-box and WD-40 domain protein 7. J Biol Chem.
285:34439–34446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lerner M, Lundgren J, Akhoondi S, Jahn A,
Ng HF, Moqadam Akbari F, Oude Vrielink JA, Agami R, Den Boer ML,
Grandér D and Sangfelt O: MiRNA-27a controls FBW7/hCDC4-dependent
cyclin E degradation and cell cycle progression. Cell Cycle.
10:2172–2183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Min SH, Lau AW, Lee TH, Inuzuka H, Wei S,
Huang P, Shaik S, Lee DY, Finn G, Balastik M, et al: Negative
regulation of the stability and tumor suppressor function of Fbw7
by the Pin1 prolyl isomerase. Mol Cell. 46:771–783. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H,
Gao J, Zhang B, Xu W, Liu J, et al: ERK kinase phosphorylates and
destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell
Res. 25:561–573. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheng Y and Li G: Role of the ubiquitin
ligase Fbw7 in cancer progression. Cancer Metastasis Rev. 31:75–87.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Churi CR, Shroff R, Wang Y, Rashid A, Kang
HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, et al:
Mutation profiling in cholangiocarcinoma: Prognostic and
therapeutic implications. PLoS One. 9:e1153832014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yu J, Zhang W, Gao F, Liu YX, Chen ZY,
Cheng LY, Xie SF and Zheng SS: FBW7 increases chemosensitivity in
hepatocellular carcinoma cells through suppression of
epithelial-mesenchymal transition. Hepatobiliary Pancreat Dis Int.
13:184–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Z, Fukushima H, Gao D, Inuzuka H, Wan
L, Lau AW, Liu P and Wei W: The two faces of FBW7 in cancer drug
resistance. BioEssays. 33:851–859. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Biliran H Jr, Banerjee S, Thakur A, Sarkar
FH, Bollig A, Ahmed F, Wu J, Sun Y and Liao JD: C-Myc-induced
chemosensitization is mediated by suppression of cyclin D1
expression and nuclear factor-kappa B activity in pancreatic cancer
cells. Clin Cancer Res. 13:2811–2821. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
von Bueren AO, Oehler C, Shalaby T, von
Hoff K, Pruschy M, Seifert B, Gerber NU, Warmuth-Metz M, Stearns D,
Eberhart CG, et al: C-MYC expression sensitizes medulloblastoma
cells to radio- and chemotherapy and has no impact on response in
medulloblastoma patients. BMC Cancer. 11:742011. View Article : Google Scholar : PubMed/NCBI
|
